Olaparib Delays Disease Progression as First-Line Treatment in Advanced Ovarian Cancer


Olaparib (Lynparza, Merck and AstraZeneca) demonstrated significant improvement in progression-free survival in the first-line maintenance setting for women with advanced BRCA-mutated ovarian cancer.

Olaparib (Lynparza, Merck and AstraZeneca) improved progression-free survival (PFS) as a first-line treatment in women with BRCA-mutated (BRCAm) advanced ovarian cancer in a phase 3 trial, according to a press release.

The SOLO-1 phase 3 trial evaluated the efficacy and safety of olaparib tablets as a first-line maintenance monotherapy compared with placebo in patients with BRCAm advanced ovarian cancer. The trial included 391 patients with a deleterious or suspected deleterious BRCA1 or BRCA2 mutation who were in clinical complete or partial response following platinum-based chemotherapy.

The primary endpoint of the trial was PFS and key secondary endpoints included time to second disease progression or death and overall survival.

In the study, women were either treated with olaparib 300-mg tablets twice daily or placebo tablets twice daily. Those who received olaparib had a statistically significant and clinically meaningful improvement in PFS compared with a placebo. Olaparib also demonstrated a consistent safety and tolerability profile.

Related Coverage: FDA OKs Rucaparib as Maintenance Treatment of Recurrent Ovarian Cancer

“For the first time, we see a significant and clinically impactful improvement in progression-free survival in the first-line maintenance setting for women with BRCA-mutated ovarian cancer treated with a PARP inhibitor,” Sean Bohen, executive vice president, global medicines development and chief medical officer at AstraZeneca, said in a press release. “The SOLO-1 data reinforce the importance of knowing BRCA status at diagnosis, as this may enable women with BRCA-mutated ovarian cancer to receive Lynparza earlier.”

Olaparib is not currently approved for first-line maintenance treatment of ovarian cancer. It is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCAm advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy.

In addition to SOLO-1, the ongoing GINECO/ENGOTov25 phase 3 trial, PAOLA-1, is testing the effect of olaparib in combination with bevacizumab as a first-line maintenance treatment in women with newly diagnosed advanced ovarian cancer, regardless of their BRCA status.


Lynparza (olaparib) significantly delays disease progression in phase 3 first-line SOLO-1 trial for ovarian cancer [news release]. Merck’s website. http://www.mrknewsroom.com/news-release/oncology/lynparza-olaparib-significantly-delays-disease-progression-phase-3-first-line-. Accessed June 28, 2018.

Related Videos
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.